Subscribe

GI Innovation, Inc. (358570.KQ)

KRW7,620.00 +290.00 (+3.96%)
KR KOE Healthcare Biotechnology
Address Room 1116 of A-dong, Songpa-daero 167 5855
Seoul, KR
IPO 2023-03-30
ISIN KR7358570000

Explore sections of this company profile

Description

GI Innovation, Inc. specializes in the research and creation of biopharmaceutical products. Its current developmental portfolio features drug candidates G-101, G-102, G-301, and G-108. Founded by Jang Myoung-ho on July 19, 2017, the company's main operations are situated in Seoul, South Korea.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
KRW7,620.00 +290.00 (+3.96%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
779.0K
Beta
0.27
Float Shares
48.03M
Free Float %
74.8%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-8.93% +2.48% -10.89% -10.29% -22.94% -14.52% -18.24% +25.10% +43.01% +43.01% +43.01%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
7,620.00
Ratings Trend (MoM)
Rating 2024-11 Change
Strong Buy 0 0
Buy 0 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
64.45
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
  • Revenue growth Biotechnology: +1.6%
    +23,943.9% Q1'26: -100.0% (vs Q1'25)
  • EPS growth Biotechnology: +29.7%
    +50.7% Q1'26: +26.0% (vs Q1'25)
  • FCF margin FCF growth · Biotechnology: +16.2%
    -724.9%
  • EBIT margin Biotechnology: +0.0%
    -713.6%
  • ROIC Biotechnology: -16.1%
    -50.9% Q1'26: -56.9% (vs Q1'25)
  • Share dilution Biotechnology: -3.4%
    +20.0% Q1'26: +29.9% (vs Q1'25)
  • Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×
    -0.13× Q1'26: -0.05× (vs Q1'25)
Valuation Multiples From To
DCF Interactive Model (UFCF)
Projection years:
Market assumptions
WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.44) × ERP
WACC = 99% × Ke + 1% × Kd (31.0%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
Current price: 7,620.00
Enterprise Value: Equity Value: Terminal Value: TV as % of EV:

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2023
actual
Dec 2024
actual
Dec 2025
actual
Revenue
5.32B
est: 11.50M (+46,150.9%)
24.28M
est: 198.00M (-87.7%)
5.84B
est: 63.00M (+9,166.8%)
EBITDA
-51.33B
est: -11.50M (-446,250.7%)
-54.92B
est: -198.00M (-27,635.8%)
-38.67B
est: -63.00M (-61,286.4%)
EBIT
-54.66B
est: -11.50M (-475,202.3%)
-48.26B
est: -198.00M (-24,273.7%)
-41.66B
est: -63.00M (-66,031.6%)
Net Income
-55.50B
est: -80.91B (+31.4%)
-58.78B
est: 304.90B (-119.3%)
-35.13B
est: -47.38B (+25.9%)
SGA
15.15B
est: 312.34M (+4,750.0%)
2.70B
est: 5.38B (-49.8%)
3.91B
est: 1.71B (+128.3%)
EPS
-1,257.87
est: -1,551.25 (+18.9%)
-1,127.58
est: 4,871.00 (-123.1%)
-556.15
est: -757.00 (+26.5%)
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 C- 1/5 1/5 1/5 1/5 4/5 1/5 1/5
2026-05-28 C- 1/5 1/5 1/5 1/5 4/5 1/5 1/5
2026-05-27 C- 1/5 1/5 1/5 1/5 4/5 1/5 1/5
2026-05-26 C- 1/5 1/5 1/5 1/5 4/5 1/5 1/5
2026-05-22 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-05-21 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-05-20 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-05-19 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-05-18 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-05-15 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-05-14 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-05-13 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-05-12 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-05-11 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-05-08 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-05-07 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-05-06 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-05-04 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-04-30 C- 1/5 1/5 1/5 1/5 3/5 1/5 1/5
2026-04-29 D+ 1/5 1/5 1/5 1/5 2/5 1/5 1/5
2026-04-28 D+ 1/5 1/5 1/5 1/5 2/5 1/5 1/5
2026-04-27 D+ 1/5 1/5 1/5 1/5 2/5 1/5 1/5
2026-04-24 D+ 1/5 1/5 1/5 1/5 2/5 1/5 1/5
2026-04-23 D+ 1/5 1/5 1/5 1/5 2/5 1/5 1/5
2026-04-22 D+ 1/5 1/5 1/5 1/5 2/5 1/5 1/5
2026-04-21 D+ 1/5 1/5 1/5 1/5 2/5 1/5 1/5
2026-04-20 D+ 1/5 1/5 1/5 1/5 2/5 1/5 1/5
2026-04-17 D+ 1/5 1/5 1/5 1/5 2/5 1/5 1/5
2026-04-16 D+ 1/5 1/5 1/5 1/5 2/5 1/5 1/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-39.28B
OE per share TTM
-689.88
Owner's Yield
-4.23%
Maintenance CapEx ratio
Maint CapEx / Avg PPE
167.0%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
Total invested
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 48 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 Kodex Biotech 244580.KS 1.52% 2.18M 0.45%
2 Kodex Healthcare 266420.KS 0.43% 196.4K 0.09%
3 Kodex KOSDAQ 150 229200.KS 0.36% 10.85M 0.25%
4 SAMSUNG KODEX KOSDAQ150 LEVERAGE ETF 233740.KS 0.11% 2.50M 0.64%
5 Kodex KRX300 292190.KS 0.03% 15.4K 0.05%
6 Kodex MSCI Momentum 275280.KS 0.02% 6.2K 0.30%
7 iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF ISFE.L 0.02% 17.3K 0.74%
8 iShares MSCI Emerging Markets Small-Cap ETF EEMS 0.02% 66.9K 0.72%
9 State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L 0.02% 93.0K 0.55%
10 Schwab International Small-Cap Equity ETF SCHC 0.01% 692.8K 0.06%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives

Executive team data is not available for this company yet.

EBIT / Employee
-4.96M
Shares Outstanding
64.23M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

ESG Score History

No data available for this company.

Company data will be available after the next weekly refresh.
Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings reports

Stock splits